ESMO 2023 – GSK sets up Pfizer battle in B7-H4
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
ESMO 2023 – not so fast, Welireg
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.
ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
ESMO 2023 – Lumakras still looks like a colorectal also-ran
And first data with a low dose are particularly unimpressive.
